Raffaella Pasquale

7PUBLICATIONS
57CO-AUTHORS
Other biological sciences not elsewhere classifiedApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 02, 2026
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Luca Laurenti, Feliciana Guglielmi, Antonio Mosca

|Feb 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Francesco Autore, Alessandra Tedeschi, Giulia Benevolo

|Jan 07, 2026
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna

|Jun 12, 2025
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Alberto Fresa, Idanna Innocenti, Annamaria Tomasso

|Apr 16, 2025
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino

|Nov 19, 2024
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.

Francesco Autore, A Tedeschi, G Benevolo

Pageof 2

Frequent Collaborators

7 joint publications

Luca Laurenti

5 joint publications

Isacco Ferrarini

5 joint publications

Anna Maria Frustaci

4 joint publications

Marta Coscia